Low molecular weight additives providing passive surface modification
Endexo® surface modifying macromolecules enhance the biocompatibility of medical devices that come in contact with blood, tissue, or other biological fluids. They are low molecular weight fluoro-oligomeric additives that migrate to the top few nanometers of the device surface during the manufacturing process.
In the presence of blood, the modified surfaces are able to suppress procoagulant protein conformation, reduce platelet adhesion and inhibit platelet activation. In the presence of bacteria mediated fluids the modified surfaces are effective at reducing bacteria adhesion (up to 5 log CFU) and encrustation. Endexo® modified devices reduce thrombosis, infection and biofouling all without the use of drugs.
Endexo® platform technology can be applied to a variety of base polymers (e.g. polyurethane, polysulfone, PVC, polypropylene, and silicone) and manufacturing techniques (e.g. extrusion, solution spinning, and injection molding). Endexo® molecules become an integral part of the base material providing durable surface modification and extended efficacy compared to traditional coatings.
Advantages of Endexo® anti-thrombogenic additive technology
- Passive surface modification
- Permanent presence on all device surfaces
- No impact on device functionality
- No change to existing manufacturing processes
- Compatible with a wide range of base polymers
- Low cost technology
Commercial application of Endexo® anti-thrombogenic additive technology
Average reduction across 8,500 BioFlo™ PICCs studied (as reported by AngioDynamics):
- Reduction of 50% deep vein thrombosis
- Reduction of 59% tissue plasminogen activator
Find related information:
Learn more about the acquisition of Endexo®
Enhance the safety and performance of your bioresorbable implant
Find information on our portfolio of biodegradable polymers for medical devices